PL411824A1 - Zastosowanie kompozycji zawierającej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22 - Google Patents
Zastosowanie kompozycji zawierającej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22Info
- Publication number
- PL411824A1 PL411824A1 PL411824A PL41182403A PL411824A1 PL 411824 A1 PL411824 A1 PL 411824A1 PL 411824 A PL411824 A PL 411824A PL 41182403 A PL41182403 A PL 41182403A PL 411824 A1 PL411824 A1 PL 411824A1
- Authority
- PL
- Poland
- Prior art keywords
- composition containing
- antibody conjugates
- application
- containing monomeric
- calicheamicin derivative
- Prior art date
Links
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical class C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 title abstract 2
- 229940127121 immunoconjugate Drugs 0.000 title abstract 2
- 229930195731 calicheamicin Natural products 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
Abstract
Przedmiotem wynalazku jest zastosowanie kompozycji zawierającej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22 o zmniejszonej zawartości frakcji niskoskoniugowanej (LCF) poniżej 10% w leczeniu zaburzeń proliferacyjnych.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37744002P | 2002-05-02 | 2002-05-02 | |
US60/377,440 | 2002-05-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
PL411824A1 true PL411824A1 (pl) | 2015-08-17 |
PL224844B1 PL224844B1 (pl) | 2017-02-28 |
Family
ID=29401497
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL374523A PL222725B1 (pl) | 2002-05-02 | 2003-05-02 | Sposób wytwarzania kompozycji i kompozycja zawierająca monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22 o zmniejszonej zawartości frakcji niskoskoniugowanej |
PL413302A PL228741B1 (pl) | 2002-05-02 | 2003-05-02 | Koniugaty pochodna kalicheamycyny/przeciwciało przeciwko CD22 oraz ich zastosowanie |
PL410219A PL224150B1 (pl) | 2002-05-02 | 2003-05-02 | Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca |
PL410218A PL224001B1 (pl) | 2002-05-02 | 2003-05-02 | Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie |
PL411824A PL224844B1 (pl) | 2002-05-02 | 2003-05-02 | Zastosowanie kompozycji zawierającej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL374523A PL222725B1 (pl) | 2002-05-02 | 2003-05-02 | Sposób wytwarzania kompozycji i kompozycja zawierająca monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22 o zmniejszonej zawartości frakcji niskoskoniugowanej |
PL413302A PL228741B1 (pl) | 2002-05-02 | 2003-05-02 | Koniugaty pochodna kalicheamycyny/przeciwciało przeciwko CD22 oraz ich zastosowanie |
PL410219A PL224150B1 (pl) | 2002-05-02 | 2003-05-02 | Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca |
PL410218A PL224001B1 (pl) | 2002-05-02 | 2003-05-02 | Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie |
Country Status (34)
Country | Link |
---|---|
US (6) | US8153768B2 (pl) |
EP (3) | EP2371392B1 (pl) |
JP (5) | JP5153057B2 (pl) |
KR (2) | KR101125524B1 (pl) |
CN (1) | CN100482277C (pl) |
AU (2) | AU2003231293A1 (pl) |
BE (1) | BE2017C049I2 (pl) |
BR (3) | BRPI0309868B8 (pl) |
CA (2) | CA2871117A1 (pl) |
CR (3) | CR7557A (pl) |
CY (4) | CY1116634T1 (pl) |
DK (3) | DK3127553T3 (pl) |
EC (1) | ECSP045445A (pl) |
ES (3) | ES2593304T3 (pl) |
FR (1) | FR17C1054I2 (pl) |
HK (2) | HK1162926A1 (pl) |
HU (4) | HUE057124T2 (pl) |
IL (2) | IL164946A (pl) |
LT (3) | LT1507556T (pl) |
LU (1) | LUC00044I2 (pl) |
MX (1) | MXPA04010792A (pl) |
NL (1) | NL300903I2 (pl) |
NO (3) | NO339730B1 (pl) |
NZ (2) | NZ586071A (pl) |
PH (2) | PH12013501158B1 (pl) |
PL (5) | PL222725B1 (pl) |
PT (3) | PT1507556T (pl) |
RU (3) | RU2422157C3 (pl) |
SG (3) | SG10201700289RA (pl) |
SI (3) | SI2371392T1 (pl) |
TW (2) | TWI438010B (pl) |
UA (1) | UA88599C2 (pl) |
WO (1) | WO2003092623A2 (pl) |
ZA (2) | ZA200409752B (pl) |
Families Citing this family (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
US20110045005A1 (en) * | 2001-10-19 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
EP2371392B1 (en) * | 2002-05-02 | 2015-07-08 | Wyeth Holdings LLC | Calicheamicin derivative-carrier conjugates |
TW200539855A (en) * | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
JP5470597B2 (ja) * | 2004-05-26 | 2014-04-16 | 国立大学法人 香川大学 | 希少糖d−アロースを利用した細胞・組織・臓器保存液及び該液を用いる保存方法 |
TW200621282A (en) * | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
US20060045877A1 (en) * | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
PE20060817A1 (es) * | 2004-09-10 | 2006-10-10 | Wyeth Corp | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina |
EP1661584A1 (en) * | 2004-11-26 | 2006-05-31 | Heinz Dr. Faulstich | Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy |
US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
US20070003559A1 (en) * | 2005-07-01 | 2007-01-04 | Wyeth | Methods of determining pharmacokinetics of targeted therapies |
US7678832B2 (en) | 2005-08-16 | 2010-03-16 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amide) formulation |
SI1928503T1 (sl) | 2005-08-24 | 2012-11-30 | Immunogen Inc | Postopek za pripravo konjugatov majtansinoid protitelo |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
WO2008051245A2 (en) * | 2005-12-02 | 2008-05-02 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
WO2007067602A1 (en) * | 2005-12-06 | 2007-06-14 | Wyeth | Interleukin-11 compositions and methods of use |
KR101443752B1 (ko) | 2006-03-10 | 2014-09-26 | 와이어쓰 엘엘씨 | 항-5t4 항체 및 이의 용도 |
ES2371085T3 (es) * | 2006-05-27 | 2011-12-27 | Faulstich, Heinz, Dr. | Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación. |
PT2495307T (pt) | 2006-07-13 | 2018-05-10 | Wyeth Llc | Produção do fator ix de coagulação com padrão melhorado de glicosilação |
NZ575350A (en) | 2006-08-21 | 2012-02-24 | Synta Pharmaceuticals Corp | Bis(phenylcarbonothioyl)hydrazide derivatives |
BRPI0719250A2 (pt) * | 2006-10-12 | 2015-06-16 | Wyeth Corp | Métodos e composições com opalescência reduzida. |
EP2395077A1 (en) | 2006-11-03 | 2011-12-14 | Wyeth LLC | Glycolysis-inhibiting substances in cell culture |
EP2097097B1 (en) | 2006-12-01 | 2018-05-30 | E. R. Squibb & Sons, L.L.C. | Antibodies, in particular human antibodies, that bind cd22 and uses thereof |
US8552067B2 (en) * | 2006-12-22 | 2013-10-08 | The Regents Of The University Of California | Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses therefor |
BRPI0806680A2 (pt) * | 2007-01-16 | 2015-06-16 | Wyeth Corp | Tratamento, detecção e monitoramento de inflamação via trem-1 |
AU2008223133A1 (en) | 2007-03-02 | 2008-09-12 | Wyeth | Use of copper and glutamate in cell culture for production of polypeptides |
CN102558001B (zh) | 2007-05-22 | 2015-09-23 | 惠氏有限责任公司 | 制造酰肼的改良方法 |
PE20090309A1 (es) * | 2007-06-04 | 2009-04-18 | Wyeth Corp | Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina |
LT2211904T (lt) * | 2007-10-19 | 2016-11-25 | Seattle Genetics, Inc. | Cd19 surišantys agentai ir jų panaudojimas |
US20090169550A1 (en) * | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Therapy of rituximab-refractory rheumatoid arthritis patients |
JP2011508738A (ja) * | 2007-12-26 | 2011-03-17 | バイオテスト・アクチエンゲゼルシヤフト | Cd138発現腫瘍細胞のターゲティングを向上させる方法及び剤 |
MX341344B (es) | 2007-12-26 | 2016-08-16 | Biotest Ag | Agentes dirigidos a cd138 y sus usos. |
US9011864B2 (en) * | 2007-12-26 | 2015-04-21 | Biotest Ag | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
KR20100097753A (ko) * | 2007-12-26 | 2010-09-03 | 바이오테스트 아게 | Cd138 표적성 면역접합체 및 이의 용도 |
US20090186026A1 (en) * | 2008-01-18 | 2009-07-23 | Wyeth | Ephrin and eph receptor agonists for modulation of bone formation and resorption |
WO2009124109A1 (en) | 2008-04-04 | 2009-10-08 | The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services | Human monoclonal antibodies specific for cd22 |
FR2930443B1 (fr) * | 2008-04-29 | 2010-06-25 | Oreal | Produit extemporane de soin a base d'un lyophilisat de microorganisme et de tensioactif(s) de hlb superieur ou egal a 12 |
US8236319B2 (en) | 2008-04-30 | 2012-08-07 | Immunogen, Inc. | Cross-linkers and their uses |
CN104984360A (zh) * | 2009-06-03 | 2015-10-21 | 伊缪诺金公司 | 轭合方法 |
EP2533814A2 (en) * | 2010-02-11 | 2012-12-19 | Ablynx N.V. | Delivery of immunoglobulin variable domains and constructs thereof |
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012023085A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
HRP20220796T1 (hr) | 2010-10-01 | 2022-10-14 | ModernaTX, Inc. | Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe |
WO2012065161A2 (en) | 2010-11-12 | 2012-05-18 | Scott & White Healthcare | Antibodies to tumor endothelial marker 8 |
US20120222979A1 (en) * | 2011-03-04 | 2012-09-06 | Elwha LLC, a limited liability company of the State of Delaware | Glassy compositions |
KR102272828B1 (ko) | 2011-03-29 | 2021-07-05 | 이뮤노젠 아이엔씨 | 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조 |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
LT2750768T (lt) | 2011-08-30 | 2019-02-11 | Astex Pharmaceuticals, Inc. | Decitabino darinio kompozicijos |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3492109B1 (en) | 2011-10-03 | 2020-03-04 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US20140322758A1 (en) | 2011-10-21 | 2014-10-30 | Pfizer Inc. | Addition of iron to improve cell culture |
BR112014013694A2 (pt) | 2011-12-08 | 2017-06-13 | Biotest Ag | método para tratar uma doença, e, kit |
RS63244B1 (sr) | 2011-12-16 | 2022-06-30 | Modernatx Inc | Kompozicije modifikovane mrna |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
SG11201408626YA (en) | 2012-07-03 | 2015-03-30 | Univ Washington | Antibodies to tau |
US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
AU2013326881B2 (en) | 2012-10-04 | 2018-08-02 | Immunogen, Inc. | Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates |
WO2014080251A1 (en) | 2012-11-24 | 2014-05-30 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
SG10201705150RA (en) | 2012-12-21 | 2017-07-28 | Bioalliance Cv | Hydrophilic self-immolative linkers and conjugates thereof |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
PL2992015T3 (pl) * | 2013-05-02 | 2019-01-31 | F.Hoffmann-La Roche Ag | Leczenie skojarzone niefukozylowanym przeciwciałem anty-CD20 z koniugatem przeciwciało anty-CD22-lek |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
SG11201602503TA (en) | 2013-10-03 | 2016-04-28 | Moderna Therapeutics Inc | Polynucleotides encoding low density lipoprotein receptor |
SI3066074T1 (sl) * | 2013-11-04 | 2020-03-31 | Pfizer Inc. | Intermediati in postopki za sintetizacijo derivatov kaliheamicina |
AU2014342610A1 (en) | 2013-11-04 | 2016-06-02 | Abbvie Stemcentrx Llc | Anti-EFNA4 antibody-drug conjugates |
ES2960619T3 (es) | 2014-02-28 | 2024-03-05 | Hangzhou Dac Biotech Co Ltd | Enlazadores cargados y sus usos para la conjugación |
WO2015140708A1 (en) | 2014-03-19 | 2015-09-24 | Pfizer Inc. | Method of cell culture |
US11998594B2 (en) | 2014-04-02 | 2024-06-04 | Case Western Reserve University | Anti-cancer plant virus particles linked to HER2 antigens |
MX2016016490A (es) | 2014-06-20 | 2017-07-28 | Bioalliance Cv | Conjugados de farmaco-anticuerpo anti-receptor de folato alfa (fra) y metodos de uso de los mismos. |
TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
US9925281B2 (en) | 2014-08-05 | 2018-03-27 | Case Western Reserve University | Coated plant virus imaging agents |
WO2016073972A1 (en) | 2014-11-07 | 2016-05-12 | Case Western Reserve University | Cancer immunotherapy using virus particles |
CN107735110B (zh) | 2015-04-07 | 2021-11-26 | 纪念斯隆-凯特琳癌症中心 | 纳米粒子免疫偶联物 |
JP2018515457A (ja) * | 2015-04-21 | 2018-06-14 | アッヴィ・ステムセントルクス・エル・エル・シー | カリケアマイシン構築物および使用方法 |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
US10624975B2 (en) | 2015-06-29 | 2020-04-21 | Case Western Reserve University | Anticancer drug-containing plant virus particles |
AU2016287585B2 (en) | 2015-07-02 | 2020-12-17 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
CA2991973C (en) | 2015-07-12 | 2021-12-07 | Suzhou M-Conj Biotech Co., Ltd. | Bridge linkers for conjugation of a cell-binding molecule |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
EP3725332B1 (en) * | 2015-07-16 | 2023-10-04 | Case Western Reserve University | Plant virus particles for delivery of antimitotic agents |
CA3214798A1 (en) | 2015-09-23 | 2017-03-30 | Pfizer Inc. | Cells and method of cell culture |
JP2018536404A (ja) | 2015-11-09 | 2018-12-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Cho細胞において産生したポリペプチドの品質特性を操作する方法 |
CN108713026B (zh) | 2016-01-08 | 2023-01-06 | 美国全心医药生技股份有限公司 | 四价抗psgl-1抗体及其用途 |
WO2017172907A1 (en) * | 2016-03-29 | 2017-10-05 | Sorrento Therapeutics, Inc. | Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin |
CA3019753C (en) | 2016-04-05 | 2021-10-26 | Pfizer Inc. | Cell culture process |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
EP3487527A4 (en) | 2016-07-21 | 2020-03-11 | Case Western Reserve University | PARTICLES OF VEGETABLE OR VIRAL-LIKE PARTICLES |
WO2018085658A1 (en) | 2016-11-03 | 2018-05-11 | Case Western Reserve University | Melt processed viral nanoparticle constructs |
CN110099682B (zh) | 2016-11-14 | 2023-03-31 | 杭州多禧生物科技有限公司 | 偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用 |
US11590183B2 (en) | 2017-03-10 | 2023-02-28 | Case Western Reserve University | Cancer immunotherapy using virus particles |
WO2018167621A1 (en) | 2017-03-16 | 2018-09-20 | Pfizer Inc. | Tyrosine prototrophy |
CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
US11672840B2 (en) | 2017-05-17 | 2023-06-13 | Case Western Reserve University | Anticancer trail-targeted plant virus particles |
MX2020001233A (es) | 2017-08-03 | 2020-07-20 | Otsuka Pharma Co Ltd | Compuesto farmaceutico y metodos de purificacion del mismo. |
CN111868223A (zh) | 2017-09-15 | 2020-10-30 | 百时美施贵宝公司 | 大规模生产目的多肽过程中的在线生物质电容监测 |
JP7066837B2 (ja) | 2017-10-13 | 2022-05-13 | ハープーン セラピューティクス,インク. | B細胞成熟抗原結合タンパク質 |
WO2019084555A1 (en) | 2017-10-27 | 2019-05-02 | Case Western Reserve University | TYMOVIRUS VIRUSES AND VIRAL TYPE PARTICLES USEFUL AS NANOVECTORS FOR IMAGING AND THERAPEUTIC AGENTS |
WO2019178489A1 (en) | 2018-03-16 | 2019-09-19 | Bristol-Myers Squibb Company | Metabolic enzyme activity and disulfide bond reduction during protein production |
CN110507824A (zh) * | 2018-05-21 | 2019-11-29 | 荣昌生物制药(烟台)有限公司 | 一种抗间皮素抗体及其抗体药物缀合物 |
EP3858863A1 (en) * | 2018-05-30 | 2021-08-04 | AbbVie Stemcentrx LLC | Anti-sez6 antibody drug conjugates and methods of use |
WO2020069028A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
MX2021005808A (es) | 2018-11-20 | 2021-07-02 | Univ Cornell | Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer. |
WO2020115655A1 (en) | 2018-12-06 | 2020-06-11 | Pfizer Inc. | Cells with reduced inhibitor production and methods of use thereof |
MX2021011320A (es) | 2019-03-19 | 2021-12-10 | Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron | Terapia de combinacion con omomyc y un anticuerpo que se une a pd-1 o a ctla-4 para el tratamiento del cancer. |
US11390853B2 (en) | 2019-04-26 | 2022-07-19 | Case Western Reserve University | Freeze dried viral nanoparticle constructs |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
US11896676B2 (en) | 2019-08-07 | 2024-02-13 | Case Western Reserve University | Targeting cancer cells and tissue using filamentous plant virus particles |
EP4069312A4 (en) * | 2019-12-04 | 2024-03-27 | The Research Foundation for the State University of New York | COMPOSITIONS AND METHODS FOR REDUCING OFF-TARGET TOXICITY OF ANTIBODY-DRUG CONJUGATES |
MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
CN112724263B (zh) * | 2021-04-02 | 2021-08-03 | 上海偌妥生物科技有限公司 | 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用 |
KR20240046323A (ko) | 2021-07-13 | 2024-04-08 | 비온테크 에스이 | 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023148598A1 (en) | 2022-02-02 | 2023-08-10 | Pfizer Inc. | Cysteine prototrophy |
WO2024058201A1 (ja) * | 2022-09-16 | 2024-03-21 | 国立研究開発法人量子科学技術研究開発機構 | 放射性医薬組成物の中間体の製造方法、放射性医薬組成物の中間体の精製用キット |
WO2024089013A1 (en) | 2022-10-25 | 2024-05-02 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4771128A (en) * | 1986-10-10 | 1988-09-13 | Cetus Corporation | Method of purifying toxin conjugates using hydrophobic interaction chromatography |
US5037651A (en) | 1987-01-30 | 1991-08-06 | American Cyanamid Company | Dihydro derivatives of LL-E33288 antibiotics |
US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5134075A (en) | 1989-02-17 | 1992-07-28 | Oncogen Limited Partnership | Monoclonal antibody to novel antigen associated with human tumors |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
JP3179481B2 (ja) | 1990-06-27 | 2001-06-25 | プリンストン ユニバーシティ | 突然変異体p53検出用プローブ |
CZ282603B6 (cs) | 1991-03-06 | 1997-08-13 | Merck Patent Gesellschaft Mit Beschränkter Haftun G | Humanizované a chimerické monoklonální protilátky |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
US5484892A (en) * | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US6310185B1 (en) | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
MX9701075A (es) | 1994-08-12 | 1998-03-31 | Myriad Genetics Inc | Mutaciones en vivo y polimorfismos en el gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q. |
DE69534530T2 (de) | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US20020141990A1 (en) | 1996-11-01 | 2002-10-03 | Smithkline Beecham Corporation | Anti-RSV human monoclonal antibodies |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
CA2284665C (en) | 1997-03-20 | 2010-08-17 | David Fitzgerald | Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors |
US6183744B1 (en) | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
DK0999853T3 (da) * | 1997-06-13 | 2003-04-22 | Genentech Inc | Stabiliseret antostofformulering |
AT408613B (de) | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
US6183477B1 (en) * | 1998-09-04 | 2001-02-06 | Smith & Nephew, Inc. | Attachment tool for drill guide |
KR100345463B1 (ko) | 1998-11-19 | 2003-01-08 | 주)녹십자 | B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법 |
JP2000226336A (ja) * | 1998-11-30 | 2000-08-15 | Sankyo Co Ltd | 免疫グロブリン製剤 |
WO2000034784A1 (en) | 1998-12-10 | 2000-06-15 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
EP1194167B1 (en) * | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
AU6558400A (en) * | 1999-08-17 | 2001-03-13 | Novo Nordisk A/S | Stabilisation of freeze-dried cake |
AU7787100A (en) | 1999-10-12 | 2001-04-23 | Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh | Improved method for the detection of acid resistant microorganisms in a stool |
US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
EP2371392B1 (en) | 2002-05-02 | 2015-07-08 | Wyeth Holdings LLC | Calicheamicin derivative-carrier conjugates |
-
2003
- 2003-05-02 EP EP11157981.9A patent/EP2371392B1/en not_active Expired - Lifetime
- 2003-05-02 PL PL374523A patent/PL222725B1/pl unknown
- 2003-05-02 TW TW101100850A patent/TWI438010B/zh not_active IP Right Cessation
- 2003-05-02 CA CA2871117A patent/CA2871117A1/en not_active Abandoned
- 2003-05-02 SG SG10201700289RA patent/SG10201700289RA/en unknown
- 2003-05-02 RU RU2004135101A patent/RU2422157C3/ru active Protection Beyond IP Right Term
- 2003-05-02 BR BRPI0309868A patent/BRPI0309868B8/pt not_active IP Right Cessation
- 2003-05-02 US US10/428,894 patent/US8153768B2/en active Active
- 2003-05-02 DK DK16180729.2T patent/DK3127553T3/da active
- 2003-05-02 PL PL413302A patent/PL228741B1/pl unknown
- 2003-05-02 EP EP16180729.2A patent/EP3127553B1/en not_active Expired - Lifetime
- 2003-05-02 SI SI200332437T patent/SI2371392T1/sl unknown
- 2003-05-02 PL PL410219A patent/PL224150B1/pl unknown
- 2003-05-02 HU HUE16180729A patent/HUE057124T2/hu unknown
- 2003-05-02 WO PCT/US2003/013910 patent/WO2003092623A2/en active Application Filing
- 2003-05-02 SG SG200607459-5A patent/SG165158A1/en unknown
- 2003-05-02 PL PL410218A patent/PL224001B1/pl unknown
- 2003-05-02 TW TW092112147A patent/TWI379693B/zh not_active IP Right Cessation
- 2003-05-02 CN CNB038152606A patent/CN100482277C/zh not_active Expired - Lifetime
- 2003-05-02 BR BR122019027966A patent/BR122019027966B8/pt not_active IP Right Cessation
- 2003-05-02 CA CA002483552A patent/CA2483552A1/en not_active Abandoned
- 2003-05-02 LT LTEP03724432.4T patent/LT1507556T/lt unknown
- 2003-05-02 NZ NZ586071A patent/NZ586071A/en not_active IP Right Cessation
- 2003-05-02 KR KR1020117009631A patent/KR101125524B1/ko active Protection Beyond IP Right Term
- 2003-05-02 SG SG2011035912A patent/SG187991A1/en unknown
- 2003-05-02 JP JP2004500808A patent/JP5153057B2/ja not_active Expired - Lifetime
- 2003-05-02 PT PT37244324T patent/PT1507556T/pt unknown
- 2003-05-02 DK DK03724432.4T patent/DK1507556T3/en active
- 2003-05-02 KR KR1020047017670A patent/KR101062628B1/ko active Protection Beyond IP Right Term
- 2003-05-02 EP EP03724432.4A patent/EP1507556B1/en not_active Expired - Lifetime
- 2003-05-02 ES ES03724432.4T patent/ES2593304T3/es not_active Expired - Lifetime
- 2003-05-02 HU HUE11157981A patent/HUE027590T2/hu unknown
- 2003-05-02 ES ES16180729T patent/ES2916174T3/es not_active Expired - Lifetime
- 2003-05-02 PL PL411824A patent/PL224844B1/pl unknown
- 2003-05-02 LT LTEP16180729.2T patent/LT3127553T/lt unknown
- 2003-05-02 SI SI200332621T patent/SI3127553T1/sl unknown
- 2003-05-02 ES ES11157981.9T patent/ES2545745T3/es not_active Expired - Lifetime
- 2003-05-02 SI SI200332489A patent/SI1507556T1/sl unknown
- 2003-05-02 HU HUE03724432A patent/HUE030806T2/hu unknown
- 2003-05-02 AU AU2003231293A patent/AU2003231293A1/en not_active Abandoned
- 2003-05-02 PT PT111579819T patent/PT2371392E/pt unknown
- 2003-05-02 MX MXPA04010792A patent/MXPA04010792A/es active IP Right Grant
- 2003-05-02 BR BR122019027974-8A patent/BR122019027974B1/pt not_active IP Right Cessation
- 2003-05-02 NZ NZ573563A patent/NZ573563A/en not_active IP Right Cessation
- 2003-05-02 UA UA20041209865A patent/UA88599C2/ru unknown
- 2003-05-02 DK DK11157981.9T patent/DK2371392T3/en active
- 2003-05-02 PT PT161807292T patent/PT3127553T/pt unknown
- 2003-11-03 US US10/699,874 patent/US8747857B2/en active Active
-
2004
- 2004-10-28 NO NO20044663A patent/NO339730B1/no not_active IP Right Cessation
- 2004-10-28 CR CR7557A patent/CR7557A/es not_active Application Discontinuation
- 2004-11-01 IL IL164946A patent/IL164946A/en active Protection Beyond IP Right Term
- 2004-11-22 EC EC2004005445A patent/ECSP045445A/es unknown
- 2004-12-01 ZA ZA200409752A patent/ZA200409752B/xx unknown
-
2005
- 2005-04-27 HK HK12103376.4A patent/HK1162926A1/xx not_active IP Right Cessation
- 2005-04-27 HK HK05103600.1A patent/HK1070825A1/zh not_active IP Right Cessation
-
2009
- 2009-06-26 AU AU2009202609A patent/AU2009202609B2/en active Active
-
2010
- 2010-05-31 ZA ZA2010/03874A patent/ZA201003874B/en unknown
-
2011
- 2011-03-09 RU RU2011108928A patent/RU2602878C3/ru active Protection Beyond IP Right Term
- 2011-09-29 JP JP2011215042A patent/JP5441971B2/ja not_active Expired - Lifetime
-
2012
- 2012-02-13 US US13/372,172 patent/US8835611B2/en not_active Expired - Lifetime
- 2012-07-02 CR CR20120364A patent/CR20120364A/es unknown
-
2013
- 2013-03-26 JP JP2013064065A patent/JP5756489B2/ja not_active Expired - Lifetime
- 2013-06-06 PH PH12013501158A patent/PH12013501158B1/en unknown
- 2013-06-06 PH PH12013501159A patent/PH12013501159B1/en unknown
- 2013-08-09 CR CR20130390A patent/CR20130390A/es unknown
-
2014
- 2014-01-26 IL IL230659A patent/IL230659A/en active IP Right Grant
- 2014-03-07 US US14/201,184 patent/US9351986B2/en not_active Expired - Fee Related
- 2014-12-18 JP JP2014256667A patent/JP2015061875A/ja active Pending
-
2015
- 2015-08-21 CY CY20151100732T patent/CY1116634T1/el unknown
-
2016
- 2016-05-03 US US15/145,238 patent/US20160303252A1/en not_active Abandoned
- 2016-09-05 CY CY20161100872T patent/CY1117973T1/el unknown
- 2016-09-08 NO NO20161431A patent/NO344509B1/no not_active IP Right Cessation
- 2016-10-24 RU RU2016141576A patent/RU2678818C2/ru active
-
2017
- 2017-01-26 JP JP2017011948A patent/JP6872376B2/ja not_active Expired - Lifetime
- 2017-10-25 LU LU00044C patent/LUC00044I2/fr unknown
- 2017-10-25 HU HUS1700038C patent/HUS1700038I1/hu unknown
- 2017-10-31 NL NL300903C patent/NL300903I2/nl unknown
- 2017-11-03 CY CY2017035C patent/CY2017035I2/el unknown
- 2017-11-08 LT LTPA2017036C patent/LTC2371392I2/lt unknown
- 2017-11-16 BE BE2017C049C patent/BE2017C049I2/fr unknown
- 2017-11-21 NO NO2017061C patent/NO2017061I1/no unknown
- 2017-11-30 FR FR17C1054C patent/FR17C1054I2/fr active Active
-
2018
- 2018-07-30 US US16/048,511 patent/US20180339058A1/en not_active Abandoned
-
2022
- 2022-01-14 CY CY20221100035T patent/CY1124900T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL411824A1 (pl) | Zastosowanie kompozycji zawierającej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22 | |
CY1105349T1 (el) | Θειαζολυλ-αναστολεις τυροκινασεων της οικογενειας tec | |
CY1109626T1 (el) | Ενωσεις με ιδιοτητες αποδεσμευσης αυξητικης ορμονης | |
SG196835A1 (en) | Human anti-b7rp1 neutralizing antibodies | |
CY1118951T1 (el) | Χρηση αντισωματων υποδοχεα ιντερλευκινης-4 και συνθεσεις αυτων | |
EA200301159A1 (ru) | Цитотоксические иммуноконъюгаты антитела к cd44 | |
CY1110225T1 (el) | Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης | |
MA30153B1 (fr) | Anticorps anti-ox40l et methodes correspondantes | |
HN2002000275A (es) | Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados | |
MEP32608A (en) | Antibodies to opgl | |
CY1108691T1 (el) | Πολυπεπτιδια | |
BR0211390A (pt) | Tratamento de infecções da unha com no | |
DK1718677T3 (da) | Monovalente antistoffragmenter egnede som terapeutiske midler | |
LU91758I2 (fr) | Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®) | |
CY1112687T1 (el) | Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες | |
NO20075985L (no) | Stabil emulsjonsforbindelse | |
BR0317593A (pt) | Formas de dosagem compreendendo um inibidor de cetp e um inibidor de hmg-coa reductase | |
EA200601288A1 (ru) | Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение | |
TW200602076A (en) | O, O'-amidomalonate and N, O-amidomalonate platinum complexes | |
ATE364595T1 (de) | Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika | |
DE60206272D1 (de) | Chelatorkonjugate mit verbesserten eigenschaften | |
CY1109238T1 (el) | Δισκιο περιεχον σετιριζινη και ψευδοεφεδρινη | |
NO20071378L (no) | Tiazolo-naftylsyrer. | |
RS51694B (en) | NEW PERINDOPRIL AND PHARMACEUTICAL COMPOSITIONS CONTAINING THERE | |
DE50204688D1 (de) | N-alkylaziridinoprepolymere als dentalmasse |